Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado. Show more

6200 Lookout Road, Boulder, CO, 80301, United States

Biotechnology

Healthcare

Market Cap

1.661B

52 Wk Range

$13.30 - $30.98

Previous Close

$27.77

Open

$27.89

Volume

856,867

Day Range

$27.32 - $28.91

Enterprise Value

1.199B

Cash

462.6M

Avg Qtr Burn

-15.84M

Insider Ownership

8.21%

Institutional Own.

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ELVN-001 Details Chronic Myeloid Leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELVN-002 w/ trastuzumab +/- chemotherapeutic agents Details Cancer, Metastatic breast cancer, Metastatic colorectal cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELVN-002 monotherapy Details Cancer, Solid tumor/s, Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.